Cerebrolysin dosage and evidence

What is Cerebrolysin?

How does Cerebrolysin work?

Parts of the mix act like BDNF and NGF, proteins that help brain cells survive and grow. They switch on signals that protect brain cells.

What have studies in people found about Cerebrolysin?

Cerebrolysin has been used in hospitals for decades and has many trials behind it. But the two independent reviews of it reach a different answer from the trials and reviews backed by its maker. Both sides are set out below. The disagreement between them is the most important fact on this page.

• Stroke review: an independent Cochrane review pooled 7 trials in 1,773 people with a recent stroke caused by a clot. Deaths from any cause were about the same with or without cerebrolysin (6 trials, 1,689 people), and the reviewers were moderately sure of that. They also found moderate evidence that serious side effects that did not kill may go up. None of the trials reported how well people could function afterwards, early deaths or quality of life.
• A large stroke trial in Asia: 1,070 patients. On its main combined measure there was no clear difference from a dummy drip. A look back afterwards hinted at a benefit in the most severe strokes, those scoring above 12 on a stroke severity scale.
• Dementia review: an independent Cochrane review pooled 6 trials in 597 people with dementia caused by poor blood flow to the brain. Thinking scores improved a little, and 2.69 times as many people improved overall. The reviewers rated both answers very low quality. Wherever funding was reported, drug companies paid for the trials. No new trials had appeared since the 2013 version of the review.
• Arm recovery after stroke: two matching trials pooled data on 442 patients. They got 30 mL a day for 3 weeks, starting 24 to 72 hours after the stroke, along with standard rehab. Arm function at day 90 favoured cerebrolysin by an amount the authors call moderate. The test ranked patients against each other instead of using one measure fixed in advance.
• Alzheimer's: 279 people got 10, 30 or 60 mL, or a dummy drip, for 24 weeks. Only the smallest dose, 10 mL, improved thinking scores. The 30 and 60 mL doses did not. The authors call this an upside-down U-shaped dose curve.
• Dementia from poor blood flow: 242 people got 20 mL by drip on top of aspirin for 24 weeks. Their thinking scores improved 10.6 points, against 4.4 on a dummy drip. A doctor's overall rating also favoured the drug, by 0.84 points.
• Both brain injury trials pooled, 185 patients: the same small benefit at day 30 and day 90. The authors call the effect small to medium.
• Brain injury at one hospital: 142 people with moderate to severe injuries enrolled and 139 were counted. The main measure rolled 13 different rating scales into one number. At day 90 it favoured cerebrolysin by a small margin.

What this does not tell you: No trial has tested cerebrolysin for sharper thinking, memory or brain protection in healthy adults. That is what most people buying it hope for. The dementia and stroke trials took people with a diagnosed disease. The drug was given by drip into a vein in courses, not the way people use it off label. The two Cochrane reviews rated the evidence low or very low for every benefit. They were only moderately sure of one thing, and it was the negative finding on deaths. In Alzheimer's the dose worked backwards: only the lowest dose helped thinking. That is hard to square with a simple drug effect. And the product is broken-down pig brain protein, not one defined molecule. So nobody reading this can check what is in each batch.

What do people who took Cerebrolysin report?

This is what real people say happened to them, good and bad. Nobody measured it. A report cannot tell a real effect from the lift people get just from expecting it to work, from a diet or training change made at the same time, or from what was really in the vial. We still put it near the top. It is the next best thing to a study in people: what happens when real people use it, including what goes wrong.

• The discussion splits hard and stays split. One group describes it as among the more noticeable things they have used, another calls it unproven marketing, and the argument between those positions is more of the thread than any description of what happened.
• Injection is the route people describe using. Taking it up the nose is specifically argued against, with claims of lasting nerve and brain harm circulating as secondhand reports from other boards rather than as firsthand accounts, which is worth noting as a rumour pattern rather than as a finding.
• What people describe wanting from it is mood, cognition and easier opioid withdrawal, with effects said to appear within a small number of injections. Those are individual accounts, not a pattern across many posters.
• The most substantial negative raised is not a side effect but the product itself. It is a crude extract rather than a defined molecule, and batch to batch variability is treated as the core problem. A theoretical worry about provoking an immune response against the recipient's own tissue is raised in the same discussion.
• Doubt is framed as being about money as well as about the drug, with complaints that promotion comes from people earning commission. Cost is described as low relative to other injectables, which is one of the few points nobody disputes.
• Firsthand reports of nothing happening are not what the negatives here consist of. The doubters are mostly people who have not used it saying any effect is just expectation, which is a different thing and is treated as such above.

Sources: A Bluelight harm reduction thread on Cerebrolysin, read directly, September 2026. LongeCity, where most of the long form discussion of this compound lives, would not load from this environment during this pass, so this entry rests on a narrower base than the others in this file. Nothing above is attributed to any specific post and no post is reproduced.

The state of the research

The evidence, in charts

The studies we cite

• Study in people2012
  Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial (CASTA)

  It was tested properly in a large stroke trial and it did not work. 1,070 people with a recent stroke got Cerebrolysin or a dummy infusion, and nobody involved knew which. The measure the trial was built to settle came out the same in both groups. Afterwards the researchers looked again at the most severely affected patients and saw a lean toward benefit. That look happened after the results were known, so it is a hint, not a result. A trial this size would have caught a broad benefit.

  1,070 patients: the confirmatory combined endpoint showed no significant difference versus placebo; a post hoc analysis suggested a trend toward benefit in severe strokes (NIHSS above 12).

  PMID 22282884 Stroke
• Study in people2006
  A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease

  The lowest dose helped thinking and the higher doses did not, which is hard to explain. 279 patients with mild to moderate Alzheimer's got one of three doses or a dummy drip for 24 weeks, and nobody involved knew which. Only the smallest dose improved scores on the standard cognition test. The two larger doses did nothing. The authors call this an upside-down dose curve. A real drug usually does more as the dose rises, not less.

  279 patients randomized to 10, 30 or 60 mL or placebo: only the 10 mL dose improved cognition on ADAS-cog (P=0.038), with the two higher doses failing to do so. The authors describe an inverted U-shaped dose response.

  PMID 16420392 European Journal of Neurology
• Study in people2011
  Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial

  Cerebrolysin improved thinking scores in vascular dementia, on evidence later graded very weak. 242 patients took it as a drip on top of aspirin for 24 weeks, and nobody involved knew who got the real thing. Scores on the standard cognition test improved by 10.6 points against 4.4 on the dummy. A doctor's overall impression of the patient also favoured the drug. Cochrane later rated this whole body of work very low quality, and the manufacturer supported the trials.

  242 patients over 24 weeks as add-on to aspirin: ADAS-cog+ improved 10.6 points versus 4.4 on placebo (least squares mean difference -6.17) and CIBIC+ by 0.84 points. Cochrane later graded this body of evidence very low quality.

  PMID 20656516 Journal of Stroke and Cerebrovascular Diseases
• Study in people2020
  Efficacy and safety of cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial

  A brain injury trial reported a benefit using a combined score built from thirteen different scales. 142 patients were enrolled at one hospital and 139 were analysed. The combined measure at day 90 favoured cerebrolysin by a small margin. Building one number out of thirteen scales is defensible after a brain injury, where no single scale captures recovery, and it also makes a positive result easier to reach. One hospital, 139 patients, manufacturer supported.

  142 enrolled, 139 analysed at a single centre: the primary endpoint was a multidimensional ensemble of 13 outcome scales, combined Mann-Whitney 0.59 (95% CI 0.52 to 0.66, P=0.0119) at day 90.

  PMID 31897941 Neurological Sciences
• Review of studies2023
  Cerebrolysin for acute ischaemic stroke

  A review that pooled seven studies in 1,773 people who got Cerebrolysin within two days of a stroke. It found no clear benefit on deaths or recovery. The reviewers said the evidence was weak.

  Cochrane update covering seven RCTs (1,773 participants) of Cerebrolysin started within 48 hours of stroke; the reviewers found no convincing benefit on mortality or function and flagged low-certainty evidence.

  PMID 37818733 Cochrane Database of Systematic Reviews
• Review of studies2019
  Cerebrolysin for vascular dementia

  A review of Cerebrolysin in dementia caused by poor blood flow to the brain. It looked at memory, daily function and deaths. Earlier results did not agree, and the studies were not high quality.

  Updated Cochrane review of Cerebrolysin in vascular dementia assessing cognition, global function and mortality, noting inconsistent prior results and limited-quality trials.

  PMID 31710397 Cochrane Database of Systematic Reviews
• Review of studies2017
  Safety and efficacy of Cerebrolysin in motor function recovery after stroke: a meta-analysis of the CARS trials

  Arm movement after stroke recovered better on cerebrolysin, measured with an unusual statistical test. Data on 442 patients from two matching trials were pooled. Arm function at day 90 favoured cerebrolysin by an amount the authors call moderate. The test used ranks patients against each other rather than fixing one outcome in advance, which makes the result harder to interpret and easier to obtain. The manufacturer supported this work, and no independent group has repeated it with conventional measures.

  Individual patient data from two identical trials, 442 patients: Mann-Whitney effect size on the Action Research Arm Test at day 90 of 0.62 (P<0.0001). Uses a nonparametric directional test rather than a conventional single primary endpoint.

  PMID 28707130 Neurological Sciences
• Review of studies2021
  Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series

  Pooling both brain injury trials gives the same small benefit, from the same group of investigators. 185 patients across the two CAPTAIN trials were combined. The effect at day 30 and at day 90 was the same size, which the authors themselves describe as small to medium. This is the manufacturer-supported literature checking itself. No independent team has run a cerebrolysin brain injury trial using a single conventional measure of recovery.

  185 patients pooled across the two CAPTAIN trials: combined Mann-Whitney 0.60 at day 30 and day 90, standardised mean difference 0.31 to 0.34, which the authors describe as small to medium.

  PMID 33620612 Neurological Sciences